{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T17:54:29Z","timestamp":1783014869422,"version":"3.54.6"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404430"],"award-info":[{"award-number":["82404430"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2020A1515110361"],"award-info":[{"award-number":["2020A1515110361"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021YFC0865100"],"award-info":[{"award-number":["2021YFC0865100"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFA1500201"],"award-info":[{"award-number":["2021YFA1500201"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010877","name":"Science, Technology and Innovation Commission of Shenzhen Municipality","doi-asserted-by":"publisher","award":["JSGG20210901145403012"],"award-info":[{"award-number":["JSGG20210901145403012"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.bmcl.2025.130243","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T06:34:07Z","timestamp":1744871647000},"page":"130243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Mini review: SHEN26, a novel oral antiviral drug for COVID-19 treatment"],"prefix":"10.1016","volume":"124","author":[{"given":"Peisen","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanguan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanguang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xumu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2025.130243_bb0005","doi-asserted-by":"crossref","unstructured":"Collaborators C-MD. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet 2021;398:1700\u201312. doi:https:\/\/doi.org\/10.1016\/S0140-6736(21)02143-7.","DOI":"10.1016\/S0140-6736(21)02143-7"},{"key":"10.1016\/j.bmcl.2025.130243_bb0010","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1001\/jamaneurol.2020.2065","article-title":"Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review","volume":"77","author":"Zubair","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.bmcl.2025.130243_bb0020","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1016\/S1473-3099(20)30484-9","article-title":"Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics","volume":"20","author":"Petersen","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.bmcl.2025.130243_bb0025","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3390\/v14030579","article-title":"Therapeutic strategies against Ebola virus infection","volume":"14","author":"Liu","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.bmcl.2025.130243_bb0030","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.bmcl.2025.130243_bb0035","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1056\/NEJMoa0805715","article-title":"Zika virus outbreak on Yap Island, Federated States of Micronesia","volume":"360","author":"Duffy","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2025.130243_bb0040","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(16)00562-6","article-title":"Guillain-Barre syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study","volume":"387","author":"Cao-Lormeau","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bmcl.2025.130243_bb0045","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0140-6736(13)61492-0","article-title":"Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk","volume":"382","author":"Breban","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.bmcl.2025.130243_bb0050","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1056\/NEJMoa1306742","article-title":"Hospital outbreak of Middle East respiratory syndrome coronavirus","volume":"369","author":"Assiri","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2025.130243_bb0055","first-page":"162","article-title":"SARS-CoV-2 variant biology: immune escape, transmission and fitness","volume":"21","author":"Carabelli","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.bmcl.2025.130243_bb0060","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1002\/jmv.27588","article-title":"Omicron variant of SARS-CoV-2: genomics, transmissibility, and responses to current COVID-19 vaccines","volume":"94","author":"Araf","year":"2022","journal-title":"J Med Virol"},{"key":"10.1016\/j.bmcl.2025.130243_bb0065","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s40265-023-01926-0","article-title":"Remdesivir: a review in COVID-19","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.bmcl.2025.130243_bb0070","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s00044-021-02841-3","article-title":"Review on Molnupiravir as a promising oral drug for the treatment of COVID-19","volume":"31","author":"Zarenezhad","year":"2022","journal-title":"Med Chem Res"},{"key":"10.1016\/j.bmcl.2025.130243_bb0075","article-title":"Efficacy and safety of Nirmatrelvir\/ritonavir (Paxlovid) for COVID-19: a rapid review and meta-analysis","volume":"95","author":"Amani","year":"2023","journal-title":"J Med Virol"},{"key":"10.1016\/j.bmcl.2025.130243_bb0080","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000033024","article-title":"A phase 2\/3 study of S-217622 in participants with SARS-CoV-2 infection (phase 3 part)","volume":"102","author":"Yotsuyanagi","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bmcl.2025.130243_bb0085","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1016\/j.apsb.2023.07.007","article-title":"Azvudine reduces the in-hospital mortality of COVID-19 patients: a retrospective cohort study","volume":"13","author":"Zong","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bmcl.2025.130243_bb0090","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/em.22510","article-title":"Evaluation of the mutagenic effects of Molnupiravir and N4-hydroxycytidine in bacterial and mammalian cells by HiFi sequencing","volume":"63","author":"Miranda","year":"2022","journal-title":"Environ Mol Mutagen"},{"key":"10.1016\/j.bmcl.2025.130243_bb0095","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.5996","article-title":"Mass spectrometry-based metabolomics reveals metabolism of molnupiravir may lead to metabolic disorders and hepatotoxicity","volume":"38","author":"Chen","year":"2024","journal-title":"Biomed Chromatogr"},{"key":"10.1016\/j.bmcl.2025.130243_bb0100","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral Nirmatrelvir for high-risk, nonhospitalized adults with COVID-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2025.130243_bb0105","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.54991","article-title":"Efficacy and safety of 5-day oral ensitrelvir for patients with mild to moderate COVID-19: the SCORPIO-SR randomized clinical trial","volume":"7","author":"Yotsuyanagi","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.bmcl.2025.130243_bb0110","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s11095-023-03538-5","article-title":"Physiologically-based pharmacokinetic modeling of PAXLOVID with first-order absorption kinetics","volume":"40","author":"Sagawa","year":"2023","journal-title":"Pharm Res"},{"key":"10.1016\/j.bmcl.2025.130243_bb0115","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/cpt.2687","article-title":"Physiologically-based pharmacokinetic modeling-guided dose management of oral anticoagulants when initiating Nirmatrelvir\/Ritonavir (Paxlovid) for COVID-19 treatment","volume":"112","author":"Wang","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bmcl.2025.130243_bb0120","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2025.130243_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102582","article-title":"Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2\/3 trial","volume":"71","author":"Lu","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.bmcl.2025.130243_bb0130","article-title":"Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial","volume":"38","author":"Wang","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.bmcl.2025.130243_bb0135","article-title":"Model informed dose regimen optimizing in development of leritrelvir for the treatment of mild or moderate COVID-19","volume":"15","author":"Wang","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmcl.2025.130243_bb0140","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","article-title":"Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19","volume":"6","author":"Eastman","year":"2020","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.bmcl.2025.130243_bb0145","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41422-021-00570-1","article-title":"Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2","volume":"31","author":"Xie","year":"2021","journal-title":"Cell Res"},{"key":"10.1016\/j.bmcl.2025.130243_bb0150","series-title":"Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections","author":"Nate","year":"2017"},{"key":"10.1016\/j.bmcl.2025.130243_bb0155","doi-asserted-by":"crossref","first-page":"14014","DOI":"10.1021\/acsanm.1c03334","article-title":"Temperature-responsive multilayer films based on block copolymer-coated silica nanoparticles for long-term release of Favipiravir","volume":"4","author":"Xu","year":"2021","journal-title":"ACS Appl Nano Mater"},{"key":"10.1016\/j.bmcl.2025.130243_bb0160","first-page":"19","article-title":"Stimuli-triggered multilayer films in response to temperature and ionic strength changes for controlled favipiravir drug release","author":"Xu","year":"2024","journal-title":"Biomed Mater"},{"key":"10.1016\/j.bmcl.2025.130243_bb0165","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41392-023-01310-0","article-title":"Preclinical characterization and anti-SARS-CoV-2 efficacy of ATV014: an oral cyclohexanecarboxylate prodrug of 1\u2019-CN-4-aza-7,9-dideazaadenosine C-nucleoside","volume":"8","author":"Zhou","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bmcl.2025.130243_bb0170","series-title":"A nucleoside compound for the treatment of viral infections and its use","author":"Zhang","year":"2021"},{"key":"10.1016\/j.bmcl.2025.130243_bb0175","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/13543784.2024.2347302","article-title":"Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind phase I study in healthy subjects","volume":"33","author":"Sun","year":"2024","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.bmcl.2025.130243_bb0180","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12985-025-02631-y","article-title":"Efficacy and safety of SHEN26, a novel oral small molecular RdRp inhibitor for COVID-19 treatment: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial","volume":"22","author":"Bai","year":"2025","journal-title":"Virol J"},{"key":"10.1016\/j.bmcl.2025.130243_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112559","article-title":"Fight against novel coronavirus: a perspective of medicinal chemists","volume":"201","author":"Amin","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130243_bb0190","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2025.130243_bb0195","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.3389\/fmicb.2019.01945","article-title":"A structure-function diversity survey of the RNA-dependent RNA polymerases from the positive-strand RNA viruses","volume":"10","author":"Jia","year":"2019","journal-title":"Front Microbiol"},{"issue":"2","key":"10.1016\/j.bmcl.2025.130243_bb0200","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3390\/v10020076","article-title":"RNA dependent RNA polymerases: insights from structure, function and evolution","volume":"10","author":"Venkataraman","year":"2018","journal-title":"Viruses"},{"issue":"417\u201328","key":"10.1016\/j.bmcl.2025.130243_bb0205","article-title":"Structural basis for RNA replication by the SARS-CoV-2 polymerase","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bmcl.2025.130243_bb0210","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.abc1560","article-title":"Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by Remdesivir","volume":"368","author":"Yin","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2025.130243_bb0215","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1021\/acs.jmedchem.0c01929","article-title":"Remdesivir metabolite GS-441524 effectively inhibits SARS-CoV-2 infection in mouse models","volume":"65","author":"Li","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130243_bb0220","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s12250-021-00385-9","article-title":"A convenient and biosafe replicon with accessory genes of SARS-CoV-2 and its potential application in antiviral drug discovery","volume":"36","author":"Jin","year":"2021","journal-title":"Virol Sin"},{"key":"10.1016\/j.bmcl.2025.130243_bb0225","series-title":"A crystalline form of a nucleoside compound","author":"Li","year":"2022"},{"key":"10.1016\/j.bmcl.2025.130243_bb0230","series-title":"A large-scale preparation method for an oral antiviral drug against coronavirus infections","author":"Li","year":"2022"},{"key":"10.1016\/j.bmcl.2025.130243_bb0235","series-title":"A crystalline form of a nucleoside compound salt","author":"Li","year":"2022"},{"key":"10.1016\/j.bmcl.2025.130243_bb0240","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1021\/acs.oprd.3c00248","article-title":"Optimized kilogram-scale synthesis and impurity identification of SHEN26 (ATV014) for treating COVID-19","volume":"28","author":"Chen","year":"2023","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.bmcl.2025.130243_bb0245","series-title":"Common terminology criteria for adverse events (CTCAE)","author":"Health UDo","year":"2017"},{"key":"10.1016\/j.bmcl.2025.130243_bb0250","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1021\/acs.estlett.0c00730","article-title":"Persistence of SARS-CoV-2 in water and wastewater","volume":"7","author":"Bivins","year":"2020","journal-title":"Environ Sci Technol Lett"},{"key":"10.1016\/j.bmcl.2025.130243_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2020.126893","article-title":"SARS-CoV-2 in environmental perspective: occurrence, persistence, surveillance, inactivation and challenges","volume":"405","author":"Mohan","year":"2021","journal-title":"Chem Eng J"},{"key":"10.1016\/j.bmcl.2025.130243_bb0260","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2202871119","article-title":"Pandemic origins and a one health approach to preparedness and prevention: solutions based on SARS-CoV-2 and other RNA viruses","volume":"119","author":"Keusch","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmcl.2025.130243_bb0265","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00203-020-02040-5","article-title":"Animal and human RNA viruses: genetic variability and ability to overcome vaccines","volume":"203","author":"Villa","year":"2021","journal-title":"Arch Microbiol"},{"issue":"12","key":"10.1016\/j.bmcl.2025.130243_bb0270","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.3390\/v15122316","article-title":"The functional implications of broad spectrum bioactive compounds targeting RNA-dependent RNA polymerase (RdRp) in the context of the COVID-19 pandemic","volume":"15","author":"Comunale","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.bmcl.2025.130243_bb0275","series-title":"The use of a nucleoside compound in the preparation of products related to poxviruses","author":"Li","year":"2024"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25001520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25001520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:07:13Z","timestamp":1762344433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25001520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":54,"alternative-id":["S0960894X25001520"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130243","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mini review: SHEN26, a novel oral antiviral drug for COVID-19 treatment","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130243","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"130243"}}